Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs)
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.26535
Abstract: Checkpoint inhibitors (CPI) have revolutionized the treatment of many solid tumors. However, difficulties in production, stability, the requirement of frequent high doses for antibody administration and long intravenous administration are recurring issues. Synthetically designed DNA-encoded… read more here.
Keywords: antibodies dmabs; dna; monoclonal antibodies; dna encoded ... See more keywords